Grant: Engage Grants Program
Queen's University
$25,000.00
A biofabrication and validation platform for 3D bioprinting of physiologically complex tissue phantoms for ultrasound imaging
EF 2015-16
Résumé
Aspect Biosystems Ltd. is a development-stage biotechnology company pioneering the advancement and commercialization of novel 3D bioprinting technology to fabricate physiologically complex tissues for broad applications in the life sciences. An important new business opportunity of this technology in disease diagnosis and drug development is the creation of large, programmable, and cell-containing tissue phantoms for use in the field of ultrasound-based tissue typing. In this project we propose to optimize the printing process to build large constructs that mimic in vivo tissue stiffness, density, and ultrasound-image-signature, essential characteristics of tissue phantoms for ultrasound imaging. The main objectives are to develop the necessary biomaterial formulations and printer improvements to enable the biofabrication of large, densely packed 3D bioprinted ultrasound tissue phantoms, and to use ultrasound tissue typing parameters to evaluate and optimize
such constructs to closely mimic in vivo tissue. We aim to fabricate several tissue phantoms with controlled geometry, cell composition, and tissue stiffness using human hepatocellular liver and cervical cancer cells. The overall process will be tested for functionality, reproducibility, printability, and biocompatibility of the phantoms. Ultrasound-based tissue typing techniques including those analyzing spectral and statistical properties of individual ultrasound data frames, as well as a new approach that uses a sequence of ultrasounddata frames will be applied to characterize and optimize the bioprinted phantoms.
Development and commercialization of 3D bioprinting enabled tissue products will put Canada at the forefront of innovations in this field and has the potential to benefit the Canadian economy and advance the output of Canadian intellectual property. The tissue phantoms developed in this project will enable evaluation of new image capturing and processing techniques on structures that mimic in vivo conditions, for more accurate diagnosis of disease especially cancer as well developing new drugs and monitoring treatments, positively impacting the lives of millions of people.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
491590-2015
Name nom
Mousavi, Parvin
Department département
Computing, School of
Organization id
29
Institution établissement
Queen's University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
A biofabrication and validation platform for 3D bioprinting of physiologically complex tissue phantoms for ultrasound imaging
Keyword
NSERC
Application summary
Aspect Biosystems Ltd. is a development-stage biotechnology company pioneering the advancement and commercialization of novel 3D bioprinting technology to fabricate physiologically complex tissues for broad applications in the life sciences. An important new business opportunity of this technology in disease diagnosis and drug development is the creation of large, programmable, and cell-containing tissue phantoms for use in the field of ultrasound-based tissue typing. In this project we propose to optimize the printing process to build large constructs that mimic in vivo tissue stiffness, density, and ultrasound-image-signature, essential characteristics of tissue phantoms for ultrasound imaging. The main objectives are to develop the necessary biomaterial formulations and printer improvements to enable the biofabrication of large, densely packed 3D bioprinted ultrasound tissue phantoms, and to use ultrasound tissue typing parameters to evaluate and optimize
such constructs to closely mimic in vivo tissue. We aim to fabricate several tissue phantoms with controlled geometry, cell composition, and tissue stiffness using human hepatocellular liver and cervical cancer cells. The overall process will be tested for functionality, reproducibility, printability, and biocompatibility of the phantoms. Ultrasound-based tissue typing techniques including those analyzing spectral and statistical properties of individual ultrasound data frames, as well as a new approach that uses a sequence of ultrasounddata frames will be applied to characterize and optimize the bioprinted phantoms.
Development and commercialization of 3D bioprinting enabled tissue products will put Canada at the forefront of innovations in this field and has the potential to benefit the Canadian economy and advance the output of Canadian intellectual property. The tissue phantoms developed in this project will enable evaluation of new image capturing and processing techniques on structures that mimic in vivo conditions, for more accurate diagnosis of disease especially cancer as well developing new drugs and monitoring treatments, positively impacting the lives of millions of people.